<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109784</url>
  </required_header>
  <id_info>
    <org_study_id>PATRASCARDIOLOGY-1</org_study_id>
    <nct_id>NCT01109784</nct_id>
  </id_info>
  <brief_title>Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).</brief_title>
  <official_title>Phase 3 Study of Prasugrel vs High Dose (150 mg) Clopidogrel in Clopidogrel Resistant Patients Post Coronary Angioplasty.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of dual antiplatelet therapy is considered standard of care in patients post&#xD;
      percutaneous coronary intervention (PCI) with stenting. However, a significant proportion of&#xD;
      patients is considered clopidogrel resistant and this resistance is shown to be accompanied&#xD;
      by future adverse events. Additionally, clopidogrel resistance has been linked with the&#xD;
      CYP2C19 polymorphism. The hypothesis of the study is to define in consecutive patients&#xD;
      undergoing PCI those that are clopidogrel resistant PCI following routinely used loading as&#xD;
      estimated predischarge with the VerifyNow point of care system of platelet reactivity.&#xD;
      Clopidogrel resistant patients will be randomized in 1:1 fashion to prasugrel 10 mg or&#xD;
      clopidogrel 150mg daily. Platelet reactivity will be assessed at day 30, when treatment&#xD;
      crossover will be performed. At day 60 platelet reactivity will be determined as well. In&#xD;
      addition, in all patients genetic determination of CYP polymorphisms (including the&#xD;
      CYP2C19)known to affect clopidogrel metabolism will be performed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Reactivity Units (PRU) assessed by VerifyNow P2Y12(Accumetrics)</measure>
    <time_frame>Day 60</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Coronary Artery Disease (CAD)</condition>
  <condition>Acute Coronary Syndrome (ACS)</condition>
  <arm_group>
    <arm_group_label>prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>prasugrel per os 10mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clopidogrel per os 150mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prasugrel</intervention_name>
    <description>prasugrel 10 mg/day</description>
    <arm_group_label>prasugrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>clopidogrel per os 150mg/day</description>
    <arm_group_label>clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years old&#xD;
&#xD;
          -  Patients having PCI with stenting 24-48 hours prior randomization, for 1. Stable&#xD;
             angina 2.Ischaemia in provocative test 3.Acute coronary syndrome (unstable angina or&#xD;
             myocardial infarction)&#xD;
&#xD;
          -  Written Informed consent&#xD;
&#xD;
          -  Platelet reactivity units (PRU) (VerifyNow) &gt;230&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of bleeding diathesis&#xD;
&#xD;
          -  Chronic oral anticoagulation treatment&#xD;
&#xD;
          -  Contraindications to antiplatelet therapy&#xD;
&#xD;
          -  Known platelet function disorders&#xD;
&#xD;
          -  PCI or coronary artery bypass surgery &lt; 3 months&#xD;
&#xD;
          -  Unsuccessful PCI (residual stenosis &gt; 30% or flow &lt; Thrombolysis in myocardial&#xD;
             infarction flow 3)&#xD;
&#xD;
          -  Planned staged PCI in the next 60 days&#xD;
&#xD;
          -  Hemodynamic instability&#xD;
&#xD;
          -  Cancer or hemodialysis&#xD;
&#xD;
          -  Platelet count &lt;100 000/ μL, hematocrit &lt;30%&#xD;
&#xD;
          -  Creatinine clearance &lt;25 ml/min&#xD;
&#xD;
          -  A life expectancy&lt;1 year, inability to give informed consent&#xD;
&#xD;
          -  High likelihood of being unavailable for the Day 60 follow up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardiology Department, Patras University Hospital</name>
      <address>
        <city>Rio, Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>April 22, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <last_update_submitted>August 23, 2010</last_update_submitted>
  <last_update_submitted_qc>August 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dimitrios Alexopoulos</name_title>
    <organization>Patras University Hospital</organization>
  </responsible_party>
  <keyword>coronary angioplasty</keyword>
  <keyword>clopidogrel resistance</keyword>
  <keyword>prasugrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

